rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Gregory J. Divis

Chief Executive Officer

Company insider

Files Form 4 as: Chief Executive Officer, Avadel Pharmaceuticals; Director, Jaguar Health; CEO and President, K-V Pharmaceutical Co.

Every Form 4 they filed

In numbers

Trades disclosed
68
Buys
8
Sells
0
Bought
$728K
Sold
$0
Companies
3
Companies where not an officer
1
First trade
18 Jul 2008
Last trade
12 Feb 2026
Last filed
12 Feb 2026

Companies traded

Where they are an officer
Avadel PharmaceuticalsDirector, Officer · Biotechnology · last 12 Feb 20268 buys · 0 sells
K-V Pharmaceutical CoDirector, Officer · last 27 Sep 20130 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
JAGX Jaguar HealthDirector · Biotechnology · last 18 May 20220 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
02Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
12 Feb 2026filed 12 Feb 2026Avadel PharmaceuticalsBiotechnologySEC FORM 4 Code D$4.4M211,105 at $21.00filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—350,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—600,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—310,000filing
12 Feb 2026filed 12 Feb 2026Avadel PharmaceuticalsBiotechnologySEC FORM 4 Code D$210K10,000 at $21.00filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—150,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—150,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—100,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—50,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—100,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—400,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—500,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—310,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—350,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—600,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—310,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—100,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—50,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—100,000filing
12 Feb 2026filed 12 Feb 2026Avadel Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—400,000filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed8

Buys in green, sells in red, by the company’s sector.

Related people

Weiss Asset Management LPOther role · Other at Avadel Pharmaceuticals, filing Form 4 there in the last year
Mark Anthony McCamishDirector · Director at Avadel Pharmaceuticals, filing Form 4 there in the last year
Eric J. EndeDirector · Director at Avadel Pharmaceuticals, filing Form 4 there in the last year
Geoffrey Michael GlassDirector · Director at Avadel Pharmaceuticals, filing Form 4 there in the last year
Naseem AminDirector · Director at Avadel Pharmaceuticals, filing Form 4 there in the last year